FDA is narrowing the path for compounded GLP-1 prescriptions as national supply stabilizes. Patients using these medicines should check whether their product is FDA-approved, compounded, or made from a bulk substance, because the rules and safety concerns are not the same.
Not automatically. FDA’s March and April 2026 actions say adding B12 or using telehealth does not by itself keep compounded semaglutide available or appropriate. What matters is the prescription, the pharmacy pathway, and whether a prescriber documented a real patient-specific need.
FDA approved Icotyde on March 17, 2026, giving some adults and teens with moderate to severe plaque psoriasis a new once-daily pill option.
The FDA approved daily obesity pill orforglipron on April 1. Here is what its main placebo-controlled trial found, and what patients still do not know.
A new trial found less clinically important bleeding with apixaban than rivaroxaban after a serious clot, but treatment changes still need a clinician.
Dry mouth is more than a nuisance. Many common medicines can reduce saliva, which can raise cavity risk and make it harder to protect teeth.
Current U.S. pain guidance says arthritis care should usually start with non-opioid options, with treatment tailored to arthritis type and daily function.
Federal telehealth prescribing flexibility for ADHD stimulants continues through December 31, 2026. Here’s what changed, what did not, and where barriers remain.
With semaglutide and tirzepatide shortages resolved, the FDA is tightening scrutiny of mass-marketed compounded GLP-1s. Here is what changed and what patients should ask now.
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
The FDA has approved the first generic of Flovent HFA, but this is not a simple fix for every family affected by the brand-name inhaler’s discontinuation. Here’s what changed, who it may help, and why coverage and pharmacy access may still be uneven.
As of April 2, 2026, nothing changes at the pharmacy yet for Medicare patients taking Xeljanz, Orencia, Cosentyx, or Cimzia. What changed is that Medicare has selected these drugs for its third negotiation cycle, manufacturers are participating, and any negotiated prices would not begin until January 1, 2028.
The FDA has approved Nuzolvence, an oral form of zoliflodacin, for some uncomplicated gonorrhea cases. Here is what the phase 3 trial found, what noninferior means, and why this does not apply to every gonorrhea infection.
In 2026, Medicare beneficiaries are seeing the first real-world effects of negotiated drug prices and a new $2,000 annual out-of-pocket cap under Part D. Here’s what changed, which drugs are affected, and what to check with your plan.
In 2026, the first negotiated drug prices under Medicare’s new program take effect. Here’s what that means for seniors, how the Maximum Fair Price works, and how the $2,000 Part D cap fits in.
Drug shortages remain a nationwide issue in early 2026. Here’s what it means when a medication appears on the FDA’s Drug Shortages list, how shortages differ from recalls, and what patients should do to protect their care.
Federal agencies extended pandemic-era telehealth flexibilities for prescribing certain controlled substances, including ADHD stimulants, through December 31, 2025. Here’s what that meant, where things stand in March 2026, and how patients can avoid treatment disruptions.
Federal telehealth flexibilities allowed many ADHD stimulant prescriptions to be written without an in-person exam through December 31, 2025. Here’s what changed, where things stand in March 2026, and how patients can avoid treatment disruptions.
Medicare drug coverage has changed in recent years, including a $2,000 annual cap on out-of-pocket Part D costs. Here’s what people with Medicare should understand in 2026 about prescription costs, payment options, and coverage rules.
Recent FDA safety communications about compounded medications and ongoing drug supply shifts are raising new questions for patients. Here’s what to know about prescription safety, shortages, and how to protect yourself.
Drug recalls can sound alarming, but not all recalls carry the same level of risk. Here’s how the FDA’s recall system works, what different classifications mean, and what patients should do if a medication they use is recalled.
Dentists prescribe millions of antibiotics each year. Here’s what the latest public health guidance says about when they’re needed, when they’re not, and why it matters for your health.
End of content
End of content
